Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Blood blood.2025030816.

https://doi.org/10.1182/blood.2025030816

Published: 2025

Includes: Supplemental data

Journal Articles

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Blood (2025) 146 (19): 2293–2305.

https://doi.org/10.1182/blood.2025028730

Published: 2025

Includes: Supplemental data

Journal Articles

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

Blood (2025) 146 (Supplement 1): 1640.

https://doi.org/10.1182/blood-2025-1640

Published: 2025

Journal Articles

Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)

Thomas Schroeder, Matthias Stelljes, Edgar Jost, Jan Moritz Middeke, Gesine Bug, Georg-Nikolaus Franke, Udo Holtick, Christof Scheid, Mareike Verbeek, Caroline Pabst, Hans Christian Reinhardt, Johannes Schetelig, Nicolaus Kröger, Nadja Drusenheimer, Christina Rautenberg, Guido Kobbe

Blood (2025) 146 (Supplement 1): 4302.

https://doi.org/10.1182/blood-2025-4302

Published: 2025

Journal Articles

Transcriptomic characterization of platelets in immune thrombocytopenia indicates sustained activation and mitochondrial dysfunction

Julia-Annabell Georgi, Marita Hartwig, Ulrike Anne Friedrich, Andreas Dahl, Heidi Altmann, Thomas Stauch, Jan Moritz Middeke, Martin Bornhaeuser, Peter Bugert, Christian Thiede, Karolin Trautmann-Grill

Blood (2025) 146 (Supplement 1): 1239.

https://doi.org/10.1182/blood-2025-1239

Published: 2025

Journal Articles

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Jan-Niklas Eckardt, Ishan Srivastava, Chethan Babu, Sebastian Riechert, Tim Schmittmann, Susann Winter, Martin Schneider, Markus Badstübner, Ann-Kathrin Eisfeld, Haley Roberts, Christoph Röllig, Martin Bornhäuser, Jan Moritz Middeke, Andrew Srisuwananukorn

Blood (2025) 146 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2025-2558

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Blood (2025) 146 (Supplement 1): 5298.

https://doi.org/10.1182/blood-2025-5298

Published: 2025

Journal Articles

Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort

Blood (2025) 146 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2025-1978

Published: 2025

Journal Articles

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Maximilian Alexander Rohnert, Jonas Schadt, Michael Kramer, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Désirée Kunadt, Jan Moritz Middeke, Lars Thielecke, Friedemann Uschner, Ingmar Glauche, Christian Thiede, Martin Bornhaeuser, Uta Oelschlaegel, Malte von Bonin, Uwe Platzbecker, Claudia D Baldus, Hubert Serve, Carsten Mueller-Tidow

Blood (2024) 144 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2024-194874

Published: 2024

Journal Articles

Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy

Jan-Niklas Eckardt, Ishan Srivastava, Zizhe Wang, Susann Winter, Tim Schmittmann, Sebastian Riechert, Miriam Eva Helena Gediga, Anas Shekh Sulaiman, Martin M. K. Schneider, Freya Schulze, Christian Thiede, Katja Sockel, Frank P. Kroschinsky, Christoph Röllig, Martin Bornhäuser, Karsten Wendt, Jan Moritz Middeke

Blood (2024) 144 (Supplement 1): 1057.

https://doi.org/10.1182/blood-2024-198486

Published: 2024

Journal Articles

Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning

Dante Adami, Sebastian Riechert, Tim Schmittmann, Markus Badstübner, Karsten Wendt, Stefani Barbara Parmentier, Katja Sockel, Frank P. Kroschinsky, Martin Bornhäuser, Jan Moritz Middeke, Jan-Niklas Eckardt

Blood (2024) 144 (Supplement 1): 4975.

https://doi.org/10.1182/blood-2024-205235

Published: 2024

Journal Articles

Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms

Freya Schulze, Waldemar Hahn, Katja Sockel, Susann Winter, Markus Wolfien, Martin Bornhaeuser, Jan Moritz Middeke, Jan-Niklas Eckardt

Blood (2024) 144 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2024-210870

Published: 2024

Journal Articles

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 776.

https://doi.org/10.1182/blood-2024-204763

Published: 2024

Journal Articles

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2024-198861

Published: 2024

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

Jan-Niklas Eckardt, Ishan Srivastava, Yeqiao Xu, Kellen B Gil, Andrea A. Osypuk, Zenggang Pan, Martin M. K. Schneider, Freya Schulze, Karsten Wendt, Susann Winter, Martin Bornhäuser, Daniel A. Pollyea, Jan Moritz Middeke

Blood (2024) 144 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2024-206776

Published: 2024

Journal Articles

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Katja Sockel, Annika Neu, Maren Goeckenjan, Markus Ditschkowski, Inken Hilgendorf, Nicolaus Kröger, Francis A. Ayuk, Friedrich Stoelzel, Jan Moritz Middeke, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Matthias Fante, Daniel Wolff, Thomas Luft, Julia Winkler, Kerstin Schäfer-Eckart, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christian Junghanss, Friederike Wortmann, Susann Winter, Helga Neidlinger, Catrin Theuser, Jan Beyersmann, Martin Bornhaeuser, Sandra Schmeller, Johannes Schetelig

Blood (2024) 144 (14): 1532–1542.

https://doi.org/10.1182/blood.2024024342

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2023-187273

Published: 2023

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Blood (2023) 142 (Supplement 1): 160.

https://doi.org/10.1182/blood-2023-184445

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)

Transcriptomic characterization of platelets in immune thrombocytopenia indicates sustained activation and mitochondrial dysfunction

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy

Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning

Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms

Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only